Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 10/20 | 0.59 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CCNK | O75909 | 1/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911420 | 0.92 | USP7 (0.61) | USP7JAK1JAK3JAK2TYK2 | |
| SCHEMBL23911640 | 0.88 | USP7 (0.76) | USP7JAK1JAK3JAK2TYK2 | |
| SCHEMBL23910832 | 0.87 | USP7 (0.77) | USP7JAK3 | |
| SCHEMBL23910743 | 0.87 | USP7 (0.77) | USP7JAK3 | |
| SCHEMBL23921635 | 0.87 | USP7 (0.77) | USP7JAK3 | |
| SCHEMBL23910753 | 0.79 | USP7 (0.79) | USP7JAK3 | |
| SCHEMBL23911204 | 0.79 | USP7 (0.79) | USP7JAK3 | |
| SCHEMBL23911602 | 0.79 | USP7 (0.79) | USP7JAK3 | |
| SCHEMBL23910812 | 0.76 | MEN1 (0.37) | GPR119CCNT1 | |
| SCHEMBL23911361 | 0.75 | USP7 (1.00) | USP7JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | USP7 1/4885JAK1 3702/4885JAK3 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.